In 2021, AstraZeneca generated revenues of some 36.5 billion U.S. dollars, the fourth consecutive year with significant growth. The largest therapeutic area is oncology, responsible for more than 35 percent of the company’s total revenue. Accordingly, AstraZeneca’s best-selling product is Tagrisso, a lung cancer treatment. Tagrisso generated a total revenue of five billion U.S. dollars in 2021. Other well-known products are Symbicort, Crestor, Nexium, and Pulmicort, some of which have already lost patent protection. Interestingly, although in global focus due to its COVID-19 vaccine, AstraZeneca is not among the top 10 vaccine manufacturers.
In 2020, British-Swedish biopharmaceutical company AstraZeneca became well-known due to its highly promising COVID-19 vaccine. Codenamed AZD1222, the vaccine was the most pre-ordered COVID-19 vaccine worldwide, by far. The vaccine was originally developed at the University of Oxford’s Jenner Institute. In April 2020, the two parties announced a partnership that saw AstraZeneca take responsibility for the trials, production, marketing, and logistics. The company declared that the vaccine would be sold at cost price. Additionally, the vaccine does not require ultra-cold storage, which is different from some of the other vaccines available. Therefore, AZD1222 has become especially attractive for countries without an existing ultra-cold supply chain, as well as for developing countries.
This text provides general information. Statista assumes no
liability for the information given being complete or correct.
Due to varying update cycles, statistics can display more up-to-date
data than referenced in the text.
In the following 5 chapters, you will quickly find the 23 most important statistics relating to "AstraZeneca".